Anti-EBV Determinant Variant T cell receptor ((LC13)-1), pCDTCR1 (TCR-YC0341)

The recognition of HLA-B8-FLRGRAYGL by two archetypal TCRs was compared. One was a publicly selected TCR, LC13, that is alloreactive with HLA-B44; the other, CF34, lacks HLA-B44 reactivity because it arises when HLA-B44 is coinherited in trans with HLA-B8. Whereas the alloreactive LC13 TCR docked at the C terminus of HLA-B8-FLRGRAYGL, the CF34 TCR docked at the N terminus of HLA-B8-FLRGRAYGL, which coincided with a polymorphic region between HLA-B8 and HLA-B44. The markedly contrasting footprints of the LC13 and CF34 TCRs provided a portrait of how self-tolerance shapes the specificity of TCRs selected into the immune repertoire.

Datasheet   Add to Cart


  • Target
  • EBV Determinant Variant
  • Target Species
  • EBV
  • Epitope
  • Format
  • Non-Modified TCR
  • Allele
  • HLA-B*08:01
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • LC13
  • Host Species
  • Human


  • Introduction
  • It has been explored the in vivo memory cytotoxic T lymphocyte (CTL) response to an immunodominant HLA-B8-restricted epitope, FLRGRAYGL, from the latent EBV antigen, EBNA 3A. Remarkably, the immune response to HLA-B8-FLRGRAYGL is characterized by type III-biased TCR usage (the reproducible selection of clonal TCR sequences) identifiable in unrelated HLA-B8+ individuals.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry


45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code
    Click image to refresh the verification code.

Key Updates

Receive the latest news and insights to your inbox.